Introduction
The introduction of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs has completely transformed the management of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Many randomized controlled trials have demonstrated the efficacy of anti-VEGF molecules, with encouraging results reported (1) (2) (3) (4) (5) (6) (7) . However, data on 
Methods
This retrospective, multicenter study was conducted across 6 Italian ophthalmology departments. Medical records for consecutive patients with an angiographic subtype of subfoveal CNV secondary to AMD treated with 0.3 mg pegaptanib were retrieved. The retrospective protocol was approved by the Comitato Etico Area Pavia, IRCCS Regione Lombardia (P-20170004133; 13/02/2017), and the study was conducted in accordance with the ethical principles set forth in the Declaration of Helsinki. As the study was retrospective and patients received treatment in routine clinical ophthalmology practice settings, additional informed consent was not required. All patient data were anonymized.
Eligible patients were ≥50 years of age with subfoveal CNV with any type of angiographic lesion composition due to AMD, best-corrected visual acuity (BCVA) in the study eye of 20/25 to 20/320, and previous ATEs such as cerebrovascular accidents (CVA) and myocardial infarction (MI) within 6 months.
Exclusion criteria were defined as follows: previous treatments including laser photocoagulation, photodynamic therapy, or intravitreal anti-VEGF injection; intraocular surgery within 6 months of the day of injection; any other ocular disease that could compromise vision in the study eye; ocular hypertension or glaucoma; or uncontrolled systemic hypertension.
At baseline, a complete ophthalmologic examination of each patient was carried out, including BCVA assessment on standard Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR charts at 4 meters, slit-lamp examination, tonometry, dilated fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), and spectral-domain optical coherence tomography (SD-OCT) examination (Spectralis OCT, Heidelberg Engineering). Fluorescein angiography and ICGA were performed using scanning laser ophthalmoscopy (Heidelberg Retina Angiograph). Spectral-domain OCT was performed on all patients using a scan line pattern. Central foveal thickness (CFT) was calculated manually, measuring the distance between Bruch membrane and the internal limiting membrane on the fovea. The patients were evaluated every 6 weeks and received 0.3 mg of intravitreal pegaptanib according to a pro re nata (PRN) regimen, after an initial loading phase of 2-3 injections. Retreatment was performed in case of CNV activity as shown by intraretinal/subretinal fluid on OCT examination, and/or leakage on FA, and/or new hemorrhages on biomicroscopy. At each visit, the patients were carefully questioned about the occurrence of ATEs.
The primary outcome measure was the mean change in BCVA over 1 year of follow-up. Secondary outcome measures included changes in the CFT, the proportion of eyes improving in BCVA by >3 lines at the 12-month examination, and the assessment of side effects. The paired Student t test was used to evaluate mean changes in the BCVA and CFT. All tests were 2-tailed and the level of significance was set at p<0.05.
Results
All files of patients with AMD-related CNV at the 6 study sites over the period January 2015 to January 2016 were reviewed (n = 1,723). Overall, 23 patients (23 eyes) fulfilled the inclusion and exclusion criteria, and were recruited for the study (Tab. I); 8 patients were recruited in Pavia, 6 in Milan, 3 in Ancona, 2 in Catania, 2 in Bari, and 2 in Bassano.
Mean patient age was 71.5 ± 4.6 years and the majority (61%) were female (Tab. I). History of CVA and MI was present in in 12 and 11 patients, respectively (Tab. I). All patients were carefully examined by an internist, who was responsible for prescription of clinically indicated systemic therapy, including antihypertensive agents, anticoagulants, and cardiac medications. Choroidal neovascularization had a subfoveal location in all cases, and was type 1 in the majority of eyes (n = 18; 78%) (Tab. I).
Mean BCVA improved from 0.67 ± 0.23 logMAR at baseline (approximately corresponding to 20/100 Snellen equivalent) to 0.52 ± 0.31 logMAR at the end of follow-up (approximately corresponding to 20/40 Snellen equivalent) (p = 0.044) (Fig. 1) . A functional improvement of at least 3 ETDRS lines was obtained in 8 eyes (35%) at the 12-month examination. Eleven eyes (48%) had stable BCVA, whereas 4 eyes (17%) experienced a 3-line decrease. Mean CFT at baseline was 381 ± 111 µm, and decreased significantly to 304 ± 82 µm at the 12-month examination (p = 0.008) (Fig. 2) . The mean number of injections over the follow-up was 4.3 ± 1.3 (range 3-7) .
At the last examination visit, 5 eyes showed the presence of intraretinal cysts on SD-OCT associated with fluorescein leakage, requiring further retreatment. No systemic or ocular side effects were recorded over the follow-up. Specifically, no patient experienced further ATEs.
Discussion
Pegaptanib is a selective VEGF 165a inhibitor, which can be of benefit in the management of CNV secondary to AMD. The phase III VEGF Inhibition Study in Ocular Neovascularization (VISION) demonstrated the safety and efficacy of 6-weekly pegaptanib administration in eyes affected by all CNV subtypes related to AMD (1). Subsequently, a post hoc subgroup analysis of the VISION data showed that pegaptanib therapy vascular endothelial cells, retinal pigment epithelium, pericytes, retinal neurons, and astrocytes, confirming the hypothesis that VEGF has a key ocular homeostatic role (14) . The VEGF 165a blockade stoppage mediated by pegaptanib may be enough by itself to inhibit CNV growth. Considering that the amount of VEGF 165 is significantly greater than other VEGF isoforms, including VEGF 121 , the first isoform is thought to have a relevant role in angiogenesis. Preclinical data indicate that VEGF plays a significant neuroprotective action in conditions of ischemia. The sparing of the VEGF 121 by pegaptanib leads to preservation of the retinal ganglion cells with a consequent neuroprotective role of pegaptanib (15) . Vascular endothelial growth factor also has a protective action on the choriocapillaris, as suggested by the induced loss of choriocapillaris fenestrations and by the occlusion of the choriocapillaris lumen by intravitreal injections of bevacizumab (16) .
As well as a favorable ocular safety profile, pegaptanib has also been shown to be associated with a low rate of ATEs (10, 13, 15) . All intraocular injected anti-VEGF agents can bypass the blood-retinal barrier and reach the systemic circulation, reducing VEGF plasma levels to varying degrees. Plasma VEGF protects vascular integrity and upregulates nitric oxide; reduced basal nitric oxide synthesis and action can result in vasoconstriction, increased blood pressure, and thrombus formation (17) . Increased cardiovascular risk is a particularly relevant concern because the AMD population is already at higher risk. Vascular endothelial growth factor plays a complex role in atherosclerosis (18) . In fact, VEGF upregulates the synthesis of tissue factor, the initiator of the coagulation cascade, and inhibition of VEGF could result in antithrombotic effects. However, VEGF is an endothelial cell survival factor, so that inhibition could promote apoptosis of endothelial cells, resulting in a procoagulant action. In addition to the aforementioned upregulation of nitric oxide, a potent anticoagulant, by VEGF, VEGF also has the ability to destabilize cholesterol plaques, probably by the blocking the formation of immature surface blood vessels (19) . Some studies have reported a higher incidence of nonocular hemorrhage (20) and CVA (21) in subjects injected with a nonselective anti-VEGF treatment compared with sham injection. Overall, although concerns regarding the long-term systemic impact of anti-VEGF administration have been raised, it is important to note that the trials were not designed to detect ATEs and would in fact be underpowered for this purpose. In addition, all the trials excluded patients with recent positive history of ATEs. The current lack of data in this patient group prompted us to assess the effectiveness and the safety of pegaptanib in this retrospective study. The results are of interest because they show that even in this subgroup of patients, about one-third achieved a visual acuity improvement of at least 3 lines, with a functional stabilization in about half of all patients. The results are consistent with previously reported data from a study in patients without a history of ATEs (1, 12) . In addition, the number of injections over the 12-month follow-up was very similar to that reported in the cohort of patients treated with pegaptanib in clinical ophthalmology practices across Europe (12) . It is also interesting that, in our case series, the most frequent CNV subtype was type 1, which seems to respond well to pegaptanib, as shown previously (1, 12, 22) . was more effective in eyes characterized by treatment-naive CNV, and also in patients with earlier disease with smaller lesion size and better baseline BCVA (11) . A real-world, retrospective European study, scheduling pegaptanib administration following a PRN regimen, achieved good results, showing that more than 90% of patients lost fewer than 3 ETDRS lines from baseline, whereas a BCVA gain of more 3 lines was achieved by 4.8% of patients at the 12-month examination (12) .
Overall, the effectiveness of pegaptanib in maintaining visual acuity in eyes affected by AMD-related CNV has been confirmed, even though other anti-VEGF molecules can produce a larger functional improvement (13) . In fact, even though pan-VEGF agents rapidly and efficaciously block ocular CNV, long-term inhibition of all VEGF isoforms may result in the loss of the physiologic effects applied by VEGF 121 and VEGF 165b . VEGF is produced by several retinal cells, such as
The current results suggest that pegaptanib intravitreal injections did not precipitate any recurrent ATEs (Tab. II). However, it is not possible to say whether this fully reflects the safety profile of pegaptanib or whether concomitant anticoagulant and cardiac medications contributed to the lack of ATEs seen in this at-risk patient population.
We acknowledge that the present study has several limitations, especially regarding the relatively small number of patients (likely due to the rarity of the association between active CNV and thromboembolic events), and follow-up of only 1 year. In addition, the study has a retrospective design, and therefore other factors such as selection bias and individualized clinical management may have contributed to the study findings. Nevertheless, this is the first study specifically focused on the management of patients with a history of ATEs who were therefore at particular risk if treated with anti-VEGF therapy.
In conclusion, our results suggest that intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs. We encourage further research in larger patient groups to confirm and extend these findings. 
